GeneDx Holdings Corp. (WGS) Revenue History
Annual and quarterly revenue from 2020 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
WGS Revenue Growth
Revenue Breakdown (FY 2025)
WGS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
WGS Revenue Analysis (2020–2025)
As of May 8, 2026, GeneDx Holdings Corp. (WGS) generated trailing twelve-month (TTM) revenue of $442.7 million, reflecting strong growth of +17.4% year-over-year. The most recent quarter (Q1 2026) recorded $102.3 million in revenue, down 15.5% sequentially.
Looking at the longer-term picture, WGS's 5-year compound annual growth rate (CAGR) stands at +19.0%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $427.5 million in 2025, representing a new all-time high.
Revenue diversification analysis shows WGS's business is primarily driven by Diagnostic Test (49%), Diagnostic Test, Third Party Insurance (41%), and Diagnostic Test, Institutional Customers (8%).
When compared to Healthcare sector peers including PACB (+3.9% YoY), NTRA (+35.9% YoY), and EXAS (+17.7% YoY), WGS has underperformed the peer group in terms of revenue growth. Compare WGS vs PACB →
WGS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| WGSCurrent | $443M | +17.4% | +19.0% | -2.8% | |
 PACB | $160M | +3.9% | +15.2% | -348.5% | |
 NTRA | $2.3B | +35.9% | +42.6% | -13.4% | |
 EXAS | $3.2B | +17.7% | +16.8% | -6.4% | |
 CDNA | $380M | +19.2% | +14.6% | -5.5% | |
 ILMN | $4.3B | +1.2% | +6.0% | 19.9% |
WGS Historical Revenue Data (2020–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $427.5M | +40.0% | $298.2M | 69.7% | $-11,802,000 | -2.8% |
| 2024 | $305.4M | +50.8% | $194.4M | 63.6% | $-23,213,000 | -7.6% |
| 2023 | $202.6M | -13.7% | $90.0M | 44.4% | $-180,596,000 | -89.2% |
| 2022 | $234.7M | +10.6% | $-26,750,000 | -11.4% | $-667,652,000 | -284.5% |
| 2021 | $212.2M | +18.3% | $-16,602,000 | -7.8% | $-446,149,000 | -210.3% |
| 2020 | $179.3M | - | $4.0M | 2.2% | $-241,994,000 | -134.9% |
See WGS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs WGS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare WGS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonWGS — Frequently Asked Questions
Quick answers to the most common questions about buying WGS stock.
Is WGS's revenue growth accelerating or slowing?
WGS revenue is accelerating at +17.4% year-over-year, exceeding the 5-year CAGR of +19.0%. TTM revenue reached $443M. Growth momentum has increased versus prior periods.
What is WGS's long-term revenue growth rate?
GeneDx Holdings Corp.'s 5-year revenue CAGR of +19.0% reflects the sustained expansion pattern. Current YoY growth of +17.4% is above this long-term average.
How is WGS's revenue distributed by segment?
WGS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2020-2025 are available for download. Segment mix reveals concentration and diversification trends.